NEXT

Christine Simmons

Christine Simmons

Christine Simmons writes about the New York legal community and the business of law. Email her at [email protected] and find her on Twitter @chlsimmons

Connect with this author

December 23, 2015 | New York Law Journal

Kaplan, Katzberg Dissolve White-Collar Boutique

White-collar defense boutique Kaplan & Katzberg is dissolving the end of this year, as the partners prepare to enter separate practices.

By Christine Simmons

2 minute read

December 22, 2015 | Law.com

Judge Removes Baker Hostetler Over Strategy in Fraud Case

Baker & Hostetler and partner John Moscow have been disqualified from defending real estate companies allegedly involved in laundering proceeds of a Russian fraud scheme after a federal judge found the firm's defense strategy involves attacks against a former client.

By Christine Simmons

5 minute read

December 22, 2015 | New York Law Journal

Judge Removes Baker Hostetler Over Strategy in Fraud Case

Baker & Hostetler and partner John Moscow have been disqualified from defending real estate companies allegedly involved in laundering proceeds of a Russian fraud scheme after a federal judge found the firm's defense strategy involves attacks against a former client.

By Christine Simmons

5 minute read

December 18, 2015 | New York Law Journal

Kaye Scholer Partner Indicted in 'Ponzi' Scheme

Kaye Scholer corporate partner Evan Greebel was indicted along with Martin Shkreli, a former hedge fund manager who ran the pharmaceutical company Retrophin, for their role in what federal prosecutors described as a Ponzi scheme.

By Christine Simmons

6 minute read

December 18, 2015 | New York Law Journal

Kaye Scholer Partner Indicted in 'Ponzi' Scheme

Kaye Scholer corporate partner Evan Greebel was indicted along with Martin Shkreli, a former hedge fund manager who ran the pharmaceutical company Retrophin, for their role in what federal prosecutors described as a Ponzi scheme.

By Christine Simmons

6 minute read

December 17, 2015 | The American Lawyer

Kaye Scholer Partner, Pharma Exec Plead Not Guilty to Fraud Charges

Evan Greebel, a Kaye Scholer corporate partner who joined the firm's New York office this summer, was arrested Thursday morning on charges of participating in a securities fraud scheme with former hedge fund manager-turned-pharmaceutical- executive Martin Shkreli.

By Nell Gluckman, Christine Simmons and Brian Baxter

8 minute read

December 17, 2015 | New York Law Journal

Turing CEO Martin Shkreli, Kaye Scholer Partner Arrested in Securities Probe

Martin Shkreli, the former hedge fund manager under fire for buying a pharmaceutical company and ratcheting up the price of a life-saving drug, is in custody following a securities probe. A Kaye Scholer partner is also under arrest.

By Associated Press and Christine Simmons

3 minute read

December 17, 2015 | New York Law Journal

Colbert Calls Kenyon 'Profitable' Despite Departures

Kenyon & Kenyon continues to see partner and personnel exits, including two partners who left for BakerHostetler, and the departure of the chief operating officer. The firm's new managing partner, Edward Colbert, said despite departures, the firm has become "even more profitable and viable" in the last few months.

By Christine Simmons

6 minute read

December 17, 2015 | New York Law Journal

Colbert Calls Kenyon 'Profitable' Despite Departures

Kenyon & Kenyon continues to see partner and personnel exits, including two partners who left for BakerHostetler, and the departure of the chief operating officer. The firm's new managing partner, Edward Colbert, said despite departures, the firm has become "even more profitable and viable" in the last few months.

By Christine Simmons

6 minute read

December 17, 2015 | The American Lawyer

Kaye Scholer Partner, Pharma Exec Plead Not Guilty to Fraud Charges

Evan Greebel, a Kaye Scholer corporate partner who joined the firm's New York office this summer, was arrested Thursday morning on charges of participating in a securities fraud scheme with former hedge fund manager-turned-pharmaceutical- executive Martin Shkreli.

By Nell Gluckman, Christine Simmons and Brian Baxter

8 minute read